- Also known as
- Wolverine blend · Wolverine peptide · BPC 157 TB 500 · BPC-157/TB-500 · BPC 157 and TB 500 blend
- Class
- Two-peptide research blend: a gastric pentadecapeptide and a thymosin beta-4 related peptide
- Form
- Lyophilised powder in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is Wolverine?
Wolverine blend (BPC-157 + TB-500) is a single vial holding BPC-157 5 mg and TB-500 5 mg as one lyophilised powder. The two are studied separately in the literature, and the studies cited on this page are those separate studies. Published work on it is in rat, human and mouse. People have received it in 4 studies, none of them controlled, which means those results cannot separate the compound from everything else that changed. It is stocked here as lyophilised powder in 10 mg vials, for laboratory work only. It is not authorized as a medicine and is not for use in any living subject.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Lee E et al.2021 · Altern Ther Health Med · PMID 34324435 | Human, retrospective chart review with phone survey (n=16, knee pain); 4 of the 16 received BPC-157 and TB4 | Intra-articular BPC-157 alone (n=12) or BPC-157 and TB4 as two peptide injections (n=4); amounts not stated in the abstract | Most patients surveyed 6 months to 1 year after the injection | Eleven of 12 given BPC-157 alone reported significant improvement in knee pain. Of the 4 given both peptides, 75% reported significant improvement and 25% had no relief. No specific tools were used to measure function or quality of life, and there was no control group. |
| Lee E et al.2024 · Altern Ther Health Med · PMID 39325560 | Human, uncontrolled pilot study (n=12 women with interstitial cystitis), private clinic | 10 mg total, given by injection around the inflamed area of the bladder during cystoscopy | Single procedure; follow-up period not stated in the abstract | Ten of 12 patients reported complete resolution of symptoms and 2 of 12 rated their success at 80%. No adverse events were reported. The study had no control group. |
| Lee E et al.2025 · Altern Ther Health Med · PMID 40131143 | Human, safety pilot (n=2 adults), private clinic | 10 mg in 250 cc normal saline over one hour on day 1, then 20 mg on day 2 (intravenous) | 3 days | The infusions produced no measurable effects on the tested heart, liver, kidney and thyroid biomarkers or blood glucose, and no side effects were reported. |
| Sun YS et al.2025 · World J Gastroenterol · PMID 41278163 | Human colonic mucus (IBS patients); mouse and rat (Tβ4-deficient) models | Not stated in the abstract | Not stated in the abstract | Tβ4 treatment of mice reduced tight junction proteins in the gut lining, and Tβ4 released from mast cells under stress disrupted the intestinal epithelial barrier. |
| Perovic D et al.2019 · J Orthop Surg Res · PMID 31266512 | Rat, spinal cord compression injury model | 200 or 2 μg/kg, one intraperitoneal injection 10 min after injury | Assessed at 1, 4, 7, 15, 30, 90, 180 and 360 days | Injured rats given BPC-157 showed better tail motor function, no autotomy and resolved spasticity by day 15, with less axon loss, oedema and motoneuron loss on microscopy. |
| Maar K et al.2025 · Int J Mol Sci · PMID 40362372 | Mouse, permanent coronary ligation (heart attack) model; human cardiac cells | Systemic TB4 injection; amount not stated in the abstract | Not stated in the abstract | TB4 raised miR139-5p expression and modulated ROCK1 protein levels in mouse hearts and human cardiac cells, and may reverse or inhibit fibroblast-to-myofibroblast transformation. |
| Li H et al.2018 · J Gene Med · PMID 29972714 | Mouse, CCl4-induced liver fibrosis model (gene delivery, not peptide); liver cells in vitro | Intraperitoneal adeno-associated virus encoding Tβ4 (AAV-Tβ4); amount not stated in the abstract | Not stated in the abstract | AAV-Tβ4 pre-treatment significantly reduced liver injury, collagen deposition, stellate cell activation and pro-fibrotic cytokines. |
| Li Y et al.2025 · J Allergy Clin Immunol · PMID 39978686 | Mouse, house dust mite allergic asthma model (BDCA2-DTR mice); cell experiments | Tβ4 supplementation; amount not stated in the abstract | Not stated in the abstract | Tβ4 supplementation reversed the worsened asthma phenotype in mice depleted of plasmacytoid dendritic cells, and Tβ4 inhibited IL-4/IL-13-induced JAK1/STAT6 signalling in macrophages. |
What these studies don't show: The human work here is uncontrolled: pilot studies, case reports and retrospective reviews. Without a control group these cannot show the compound caused what was observed. Neither duration nor sample size supports a safety conclusion. Knowing the vial holds what the label says is not the same as knowing the compound does anything.
Every study links to its PubMed record. See all Wolverine studies in the research library →
Wolverine price in Canada: 10mg vial
Buy BPC 157 TB 500 (Wolverine) in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $71.00 | $7.10/mg |
Starter kit
Is Wolverine available in Canada?
No product containing Wolverine blend (BPC-157 + TB-500) holds a Drug Identification Number in Canada. Nothing about its safety, efficacy or quality has been reviewed by a regulator here. Borealis Peptides holds it for in-vitro research; it is not supplied for use in any living subject. How Health Canada treats research peptides →
Side effects reported in studies
Where a cited study reported on tolerability, its wording is carried over unchanged below. Human work of this size does not establish a safety profile.
Wolverine FAQ
What is Wolverine blend (BPC-157 + TB-500)?
Suppliers and the literature both list Wolverine blend (BPC-157 + TB-500) as a two-peptide research blend: a gastric pentadecapeptide and a thymosin beta-4 related peptide. The published work on it is in rat, human and mouse. Borealis Peptides supplies it as lyophilised powder in 10 mg vials for in-vitro laboratory research. It is not a drug, and it is not supplied for use in a person or an animal. Every reference here is listed with the model it ran in and the finding as published.
Where can I buy Wolverine blend (BPC-157 + TB-500) in Canada?
Borealis Peptides ships Wolverine blend (BPC-157 + TB-500) from Canadian stock to research and business addresses in Canada. It is held in 10 mg vials. Every batch is tested by HPLC and the certificate names the batch in your vial. Orders are accepted for laboratory research only.
Is Wolverine blend (BPC-157 + TB-500) legal in Canada?
No product containing Wolverine blend (BPC-157 + TB-500) holds a Drug Identification Number in Canada. Nothing about its safety, efficacy or quality has been reviewed by a regulator here. Borealis Peptides holds it for in-vitro research; it is not supplied for use in any living subject. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much Wolverine blend (BPC-157 + TB-500) should I use?
There is none to give. Nothing on this site is a protocol, a schedule or a reconstitution volume. The amounts in the cited studies belong to those studies and to the models they ran in, and they are listed so the evidence can be weighed rather than taken on trust.
What human evidence is there for Wolverine blend (BPC-157 + TB-500)?
There is human work, but none of it is controlled. 4 studies involved people, as pilots, case reports or retrospective reviews. Without a control group these cannot show that the compound caused what was observed, and the page says so beside the table.
Does Wolverine blend (BPC-157 + TB-500) need refrigeration?
Sealed vials are held at −20 °C, dry and out of the light. Solutions are held at 2–8 °C. The lyophilised powder tolerates ambient temperature in transit, so it ships without ice and goes into the fridge on arrival. Keeping it dark and at a steady temperature matters more than how fast it arrived.
How is the purity of Wolverine blend (BPC-157 + TB-500) confirmed?
Every batch is tested by HPLC before it is sold, and the certificate refers to the batch in your vial rather than to the product in general. Keeping that batch number with your records is what makes an observation reproducible later. Certificates are available on request.
How does Wolverine blend (BPC-157 + TB-500) compare with BPC-157 and TB-500?
Each has its own published record, and comparing them is a matter of reading both. BPC-157 and TB-500 have 7 cited studies and 7 cited studies on their page against 8 here. What separates them is the published work, which both pages set out in full.
Why is Wolverine blend (BPC-157 + TB-500) named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory concerns material sold for people to inject without authorization. Borealis Peptides supplies research material for laboratory use and sells nothing for injection or for any use in a person, which is the line that advisory draws.
